Pfizer Inc (PFE)
25.13
+0.19
(+0.76%)
USD |
NYSE |
Nov 21, 16:00
25.10
-0.03
(-0.12%)
After-Hours: 20:00
Pfizer Enterprise Value: 198.27B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 198.27B |
| November 19, 2024 | 199.18B |
| November 18, 2024 | 197.82B |
| November 15, 2024 | 197.48B |
| November 14, 2024 | 204.39B |
| November 13, 2024 | 208.36B |
| November 12, 2024 | 205.36B |
| November 11, 2024 | 205.64B |
| November 08, 2024 | 208.36B |
| November 07, 2024 | 212.55B |
| November 06, 2024 | 211.99B |
| November 05, 2024 | 215.56B |
| November 04, 2024 | 214.25B |
| November 01, 2024 | 216.12B |
| October 31, 2024 | 217.31B |
| October 30, 2024 | 218.56B |
| October 29, 2024 | 218.19B |
| October 28, 2024 | 220.46B |
| October 25, 2024 | 218.13B |
| October 24, 2024 | 219.21B |
| October 23, 2024 | 220.46B |
| October 22, 2024 | 220.34B |
| October 21, 2024 | 220.85B |
| October 18, 2024 | 222.50B |
| October 17, 2024 | 222.78B |
| Date | Value |
|---|---|
| October 16, 2024 | 225.05B |
| October 15, 2024 | 223.74B |
| October 14, 2024 | 221.70B |
| October 11, 2024 | 222.16B |
| October 10, 2024 | 223.18B |
| October 09, 2024 | 227.99B |
| October 08, 2024 | 222.27B |
| October 07, 2024 | 222.38B |
| October 04, 2024 | 218.87B |
| October 03, 2024 | 217.51B |
| October 02, 2024 | 219.04B |
| October 01, 2024 | 219.38B |
| September 30, 2024 | 220.91B |
| September 27, 2024 | 226.70B |
| September 26, 2024 | 226.02B |
| September 25, 2024 | 225.79B |
| September 24, 2024 | 229.02B |
| September 23, 2024 | 227.94B |
| September 20, 2024 | 228.57B |
| September 19, 2024 | 229.93B |
| September 18, 2024 | 230.44B |
| September 17, 2024 | 230.89B |
| September 16, 2024 | 232.25B |
| September 13, 2024 | 227.72B |
| September 12, 2024 | 227.09B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
167.23B
Minimum
Dec 14 2023
352.78B
Maximum
Dec 16 2021
245.42B
Average
241.29B
Median
Enterprise Value Benchmarks
| Amgen Inc | 206.13B |
| Johnson & Johnson | 384.09B |
| Eli Lilly and Co | 742.91B |
| Merck & Co Inc | 270.08B |
| Moderna Inc | 7.348B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.465B |
| Revenue (Quarterly) | 17.70B |
| Total Expenses (Quarterly) | 12.42B |
| EPS Diluted (Quarterly) | 0.78 |
| Gross Profit Margin (Quarterly) | 70.27% |
| Profit Margin (Quarterly) | 25.22% |
| Earnings Yield | 2.94% |
| Operating Earnings Yield | 6.33% |
| Normalized Earnings Yield | 6.176 |